CN114848786A - 一种抗癌、增加免疫力的复方三参汤 - Google Patents
一种抗癌、增加免疫力的复方三参汤 Download PDFInfo
- Publication number
- CN114848786A CN114848786A CN202210474046.1A CN202210474046A CN114848786A CN 114848786 A CN114848786 A CN 114848786A CN 202210474046 A CN202210474046 A CN 202210474046A CN 114848786 A CN114848786 A CN 114848786A
- Authority
- CN
- China
- Prior art keywords
- parts
- ginseng
- compound
- decoction
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 44
- 150000001875 compounds Chemical class 0.000 title claims abstract description 33
- 230000036039 immunity Effects 0.000 title claims abstract description 21
- 201000011510 cancer Diseases 0.000 title claims description 17
- 230000001965 increasing effect Effects 0.000 title description 6
- 239000003814 drug Substances 0.000 claims abstract description 44
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 37
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 37
- 235000008434 ginseng Nutrition 0.000 claims abstract description 37
- 240000001080 Grifola frondosa Species 0.000 claims abstract description 20
- 235000007710 Grifola frondosa Nutrition 0.000 claims abstract description 20
- 240000001659 Oldenlandia diffusa Species 0.000 claims abstract description 20
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 20
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 20
- 241000251511 Holothuroidea Species 0.000 claims abstract description 18
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 16
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 16
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 16
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 16
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 15
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 15
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 15
- 235000008397 ginger Nutrition 0.000 claims abstract description 15
- 241000132012 Atractylodes Species 0.000 claims abstract description 14
- 244000197580 Poria cocos Species 0.000 claims abstract description 14
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 14
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 14
- 235000011477 liquorice Nutrition 0.000 claims abstract description 14
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 13
- 210000000582 semen Anatomy 0.000 claims abstract description 9
- 235000014347 soups Nutrition 0.000 claims abstract description 9
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 6
- 230000001093 anti-cancer Effects 0.000 claims abstract description 5
- 244000131316 Panax pseudoginseng Species 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 235000019441 ethanol Nutrition 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 230000002708 enhancing effect Effects 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 3
- 244000241838 Lycium barbarum Species 0.000 claims description 3
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 3
- 235000002789 Panax ginseng Nutrition 0.000 claims description 3
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000010025 steaming Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 244000061520 Angelica archangelica Species 0.000 claims description 2
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 2
- 239000012752 auxiliary agent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000005325 percolation Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 240000008917 Glycyrrhiza uralensis Species 0.000 claims 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 29
- 229940079593 drug Drugs 0.000 abstract description 20
- 210000004881 tumor cell Anatomy 0.000 abstract description 14
- 238000002474 experimental method Methods 0.000 abstract description 13
- 230000005764 inhibitory process Effects 0.000 abstract description 13
- 239000000203 mixture Substances 0.000 abstract description 9
- 238000011580 nude mouse model Methods 0.000 abstract description 8
- 230000006870 function Effects 0.000 abstract description 5
- 241000721047 Danaus plexippus Species 0.000 abstract description 4
- 241000699660 Mus musculus Species 0.000 abstract description 4
- 239000002671 adjuvant Substances 0.000 abstract description 4
- 230000005918 in vitro anti-tumor Effects 0.000 abstract description 4
- 230000007365 immunoregulation Effects 0.000 abstract description 3
- 241000208340 Araliaceae Species 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 description 52
- 230000000052 comparative effect Effects 0.000 description 38
- 239000000243 solution Substances 0.000 description 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 9
- 208000005718 Stomach Neoplasms Diseases 0.000 description 9
- 241000234314 Zingiber Species 0.000 description 9
- 206010017758 gastric cancer Diseases 0.000 description 9
- 201000005202 lung cancer Diseases 0.000 description 9
- 208000020816 lung neoplasm Diseases 0.000 description 9
- 201000011549 stomach cancer Diseases 0.000 description 9
- 230000012010 growth Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000022131 cell cycle Effects 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000018199 S phase Effects 0.000 description 4
- 230000001914 calming effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 description 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000037831 Polygonatum sibiricum Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- BJDYCCHRZIFCGN-UHFFFAOYSA-N pyridin-1-ium;iodide Chemical compound I.C1=CC=NC=C1 BJDYCCHRZIFCGN-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/616—Echinodermata, e.g. starfish, sea cucumbers or sea urchins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种抗癌、增加免疫力的复方三参汤,按重量份计,包含以下原料:人参2~5份、海参提取物4~7份、地参8~10份、灰树花8~10份、枸杞10~12份、白花蛇舌草16~20份、五味子10~14份、茯苓16~20份、黄精8~10份、薏苡仁28~32份、陈皮5~7份、生姜8~10份、白术4~7份、当归5~8份、甘草5~8份。本发明通过体外抗肿瘤实验、对裸鼠体内肿瘤细胞的抑制作用实验和对免疫调节作用的实验发现:以人参、海参、地参为君药,以灰树花、枸杞、白花蛇舌草、五味子为臣药,以茯苓、黄精、薏苡仁、陈皮、生姜、白术、当归为佐药,以甘草为使药,配制成的中药组合物具有显著的抗肿瘤、提高免疫力的作用。
Description
技术领域
本发明涉及中医药物领域,特别是一种抗癌、增加免疫力的复方三参汤。
背景技术
随着生态环境恶化和社会压力等各种外部环境的影响,恶性肿瘤每年呈快速增长趋势。临床上目前治疗肿瘤多采用化疗或放射性疗法,但其在杀死肿瘤细胞的同时也无选择性的杀死白细胞、淋巴细胞等人体自身免疫细胞,导致病人常常由于因自身免疫能力低下并发感染,患者使用不良反应大,且疗程长,费用高,在临床使用中有较大的局限性。
中医药在治疗肿瘤方面具有独特的优势,以中药为代表的天然类药物具有毒副作用小、作用靶点多样、耐受性好等特点,在治疗肿瘤方面愈来愈受到重视。基于此,本发明研究开发一种抗肿瘤效果好,还能增加免疫力的中药配方,具有重要意义。
发明内容
本发明的目的在于克服现有技术的不足,提供一种抗癌、增加免疫力的复方三参汤,以解决上述技术背景中提出的问题。
为实现上述目的,本发明通过以下技术方案来实现:
一种抗癌、增加免疫力的复方三参汤,按重量份计,包含以下原料:人参2~5份、海参提取物4~7份、地参8~10份、灰树花8~10份、枸杞10~12份、白花蛇舌草16~20份、五味子10~14份、茯苓16~20份、黄精8~10份、薏苡仁28~32份、陈皮5~7份、生姜8~10份、白术4~7份、当归5~8份、甘草5~8份。
优选的,一种抗癌、增加免疫力的复方三参汤,按重量份计,包含以下原料:人参3份、海参提取物6份、地参9份、灰树花9份、枸杞12份、白花蛇舌草18份、五味子12份、茯苓18份、黄精9份、薏苡仁30份、陈皮6份、生姜9份、白术6份、当归6份、甘草6份。
一种抗癌、增加免疫力的复方三参汤的制备方法,包括以下步骤:
S1、取人参、地参,加醇提取,收集渗滤液;
S2、取灰树花、枸杞、白花蛇舌草、五味子、甘草,加水提取,得水相滤液;
S3、在所述醇提取液中加入所述水相滤液,混合均匀,水浴蒸煮后备用;
S4、取茯苓、黄精、薏苡仁、陈皮、生姜、白术、当归,加水煎煮后,过滤,向滤液中加入步骤S3得到的药物和海参提取物中,混合搅匀后,根据需要浓缩得到抗癌、增加免疫力的复方三参汤。
优选的,步骤S1中,以醇溶液浸泡人参、地参,使其充分溶胀24h后渗滤收集渗滤液;其中,醇溶液为无水乙醇或95%的乙醇水溶液,醇溶液的质量为人参、地参的质量之和的6~10倍。
优选的,步骤S1中,加入水的质量为灰树花、枸杞、白花蛇舌草、五味子、甘草的质量之和的10~12倍,加水处理时间为3~5h。
优选的,步骤S4中,煎煮加入的水的质量为茯苓、黄精、薏苡仁、陈皮、生姜、白术、当归的质量之和的10~12倍,煎煮时间为3~5h。
一种抗癌、增加免疫力的复方制剂,包括如权利要求1所述的复方三参汤和可药用载体或助剂。
优选的,其剂型为颗粒剂、片剂、胶囊、丸剂、冲剂或口服液。
与现有技术相比,本发明的有益效果是:
1、本发明通过体外抗肿瘤实验、对裸鼠体内肿瘤细胞的抑制作用实验和对免疫调节作用的实验发现:以人参、海参、地参为君药,以灰树花、枸杞、白花蛇舌草、五味子为臣药,以茯苓、黄精、薏苡仁、陈皮、生姜、白术、当归为佐药,以甘草为使药,配制成的中药组合物具有显著的抗肿瘤、提高免疫力的作用。
2、本发明提供的抗癌、增加免疫力的复方三参汤对肿瘤细胞具有明显的抑制作用。通过本发明提供的工艺,制备的复方三参汤及制剂,其治疗效果明显优于通过传统方法煎煮得到中药制剂。
附图说明
图1为试验例1中各组胃癌细胞MGC-803不同周期细胞所占比例柱形图。
具体实施方式
以下通过特定的具体实例说明本发明的实施方式,本领域技术人员可由本说明书所揭露的内容轻易地了解本发明的其他优点与功效。本发明还可以通过另外不同的具体实施方式加以实施或应用,本说明书中的各项细节也可以基于不同观点与应用,在没有背离本发明的精神下进行各种修饰或改变。需说明的是,在不冲突的情况下,以下实施例及实施例中的特征可以相互组合。
本发明实施例中,各原料中药都是常用中药,在《中国药典》以及《中华本草》等中均有详细的记载,并且都可以通过商业途径容易地获得。本发明对这些中药材的产地来源等并无特别限制,只要符合相关国家标准或规定即可。如海参提取物,纯度:20:1,购于威海淼川生物科技有限公司。
本发明提供了一种抗癌、增加免疫力的复方三参汤,按重量份计,包含以下原料:人参2~5份、海参提取物4~7份、地参8~10份、灰树花8~10份、枸杞10~12份、白花蛇舌草16~20份、五味子10~14份、茯苓16~20份、黄精8~10份、薏苡仁28~32份、陈皮5~7份、生姜8~10份、白术4~7份、当归5~8份、甘草5~8份。
本发明中的术语“份”,仅指重量份,具体可将任意重量作为1份,如0.001g、0.01g、0.05g、0.1g、0.5g、1g、10g、100g、1000g、5000g、10000g等。
本发明中,人参,主补五脏,安精神,定魂魄,止惊悸,除邪气,明目,开心益智。
海参,补肾益精;养血润燥;止血;
地参,又叫地蚕、虫草参,益肾润肺,补血消疳。
灰树花,益气健脾、补虚扶正。
枸杞,补肝阴、养肝血、益精明目;
白花蛇舌草,功效:有消热解毒,消痈散疖,消肿,抗肿瘤,抗炎的作用。
五味子:益气生津,补肾宁心;
茯苓,渗湿利水、益脾和胃、宁心安神;
黄精,补气养阴、健脾润肺、益肾;
薏苡仁,健脾除湿、清热排脓及利水消肿;
陈皮,具理气降逆、调中开胃、燥湿化痰之功效。
生姜,发汗解表、温中止呕、温肺止咳、解毒;
白术:味甘,性温,健脾益气;
当归,活血化疲,补血调经;
甘草,补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药;
本发明君药为人参、海参、地参,扶正固本,补肾益气,增强机体免疫功能;臣药为灰树花、枸杞、白花蛇舌草、五味子,助人参、海参、地参扶正补虚,疏导化瘀,攻毒排毒,达到抗癌的功效;以茯苓、黄精、薏苡仁、陈皮、生姜、白术、当归为佐药提高免疫力,养血滋阴、补精益髓、补中益气,同时消除君药、臣药的毒性或烈性;以甘草使药补脾益气、调和诸药。
本发明中,所述抗癌、增加免疫力的复方三参汤的制备方法,包括以下步骤:
S1、取人参、地参,加醇提取,收集渗滤液;
S2、取灰树花、枸杞、白花蛇舌草、五味子、甘草,加水提取,得水相滤液;
S3、在所述醇提取液中加入所述水相滤液,混合均匀,水浴蒸煮后备用;
S4、取茯苓、黄精、薏苡仁、陈皮、生姜、白术、当归,加水煎煮后,过滤,向滤液中加入步骤S3得到的药物和海参提取物中,混合搅匀后,根据需要浓缩得到抗癌、增加免疫力的复方三参汤。
作为本实施例的进一步实施方式,步骤S1中,以醇溶液浸泡人参、地参,使其充分溶胀24h后渗滤收集渗滤液;其中,醇溶液为无水乙醇或95%的乙醇水溶液,醇溶液的质量为人参、地参的质量之和的6~10倍。
作为本实施例的进一步实施方式,步骤S1中,加入水的质量为灰树花、枸杞、白花蛇舌草、五味子、甘草的质量之和的10~12倍,加水处理时间为3~5h。
作为本实施例的进一步实施方式,步骤S4中,煎煮加入的水的质量为茯苓、黄精、薏苡仁、陈皮、生姜、白术、当归的质量之和的10~12倍,煎煮时间为3~5h。
抗癌、增加免疫力的复方三参汤制备所选用的原料的实施例和对比例如表1,其中实施例的制备原料记为A,制备工艺记为B。
表1
试验例1体外抗肿瘤实验
1、检测复方三参汤对肿瘤细胞生细胞生长周期的影响
本试验例以流式细胞仪检测了实施例1-3、对比例1-6的中药配方对胃癌细胞MGC-803、肝癌细胞HepG2、肺癌细胞A549生长周期的变化。
1.1药剂准备:根据实施例1-3、对比例1-6的中药配方及工艺制得的汤剂均喷雾干燥并压制成颗粒;每种配方均取0.8g,加入到40ml无血清RPMI-1640培养基中,充分震荡到完全溶解后,离心取上清液,并经0.22um过滤器过滤后,制得20mg/ml的母液备用。
1.2实验方法
复苏胃癌细胞MGC-803、肝癌细胞HepG2、肺癌细胞A549等肿瘤细胞。体外传代培养,用无血清的RPMI-1640培养液,置于37℃、5%CO2孵育箱中培养48-72h。每24h换培养液1次。待培养瓶底铺满肿瘤细胞后,弃去培养液,用0.25%胰蛋白酶消化肿瘤细胞。用无血清的RPMI-1640培养液调整细胞浓度为1x106个/ml后分别接种到各个实验组别所对应的培养基中。实验组别设空白对照组、实施例1-3、对比例1-6的中药配方实验处理组共10组。①空白对照组予常规培养液;②实验处理组均为含2mg/ml对应中药药剂+常规培养液。共同培养两代后,分别用0.25%胰蛋白酶消化,制备单细胞悬液,PBS洗涤后用-20℃预冷的乙醇固定,碘化吡啶(PI)染色后用流式细胞仪检测细胞周期的变化。统计检测结果,各组胃癌细胞MGC-803不同周期细胞所占比例见表2和图1;各组肝癌细胞HepG2不同周期细胞所占比例见表3;各组肺癌细胞A549不同周期细胞所占比例见表4。
表2各组胃癌细胞MGC-803不同周期细胞所占比例
表中,a表示与对照组相比,p<0.05;b表示与对比例2-6任一项比较,p<0.05。
通过流式细胞技术检测细胞周期,结果显示与对照组比较,不同中药配方对MG-803胃癌细胞周期起到阻滞作用,主要表现为将细胞阻滞于GO/G1期,使之不进入或延迟进入S期,干扰了DNA的合成,胃癌细胞因而丧失了进行有丝分裂的基础,增殖生长受到抑制。分别统计各组细胞的G0/G1期细胞所占比例,如表2和图1所示,结果显示实施例1-3、对比例1-6组G0/G1期细胞较对照组明显增加,差异有统计学意义。而更为重要的是实施例1-3组将胃癌细胞MGC-803阻滞于GO/G1期的能力较对比例1-6更为明显,差异具有统计学意义,揭示本发明复方三参汤的配伍合理,特别是灰树花、枸杞、白花蛇舌草、五味子一起协助人参、海参、地参,对抑制肿瘤细胞的增殖生长起到了协同增效的作用;同时实施例1-3相较于对比例1将胃癌细胞MGC-803阻滞于GO/G1期的能力更为明显,说明本发明提供的制备工艺有助于提高抑制肿瘤细胞的增殖生长的能力。
表3各组肝癌细胞HepG2不同周期细胞所占比例
细胞周期 | S期 | G2/M期 |
对照组 | 24.68±1.27 | 9.45±2.43 |
实施例1 | 40.16±2.64<sup>ab</sup> | 14.85±1.33 |
实施例2 | 41.87±3.01<sup>ab</sup> | 15.54±1.58 |
实施例3 | 42.51±3.46<sup>ab</sup> | 16.07±1.32 |
对比例1 | 38.42±2.84<sup>a</sup> | 13.16±2.71 |
对比例2 | 33.48±1.54<sup>a</sup> | 11.97±1.96 |
对比例3 | 34.81±1.17<sup>a</sup> | 12.58±2.07 |
对比例4 | 34.06±2.46<sup>a</sup> | 12.09±1.46 |
对比例5 | 35.17±2.08<sup>a</sup> | 12.94±1.55 |
对比例6 | 32.57±2.43<sup>a</sup> | 11.56±2.24 |
表中,a表示与对照组相比,p<0.05;b表示与对比例2-6任一项比较,p<0.05。
由表3可知,与对照组比较,不同中药配方对HepG2细胞周期起到阻滞作用,主要表现为将细胞阻滞于S及G2期。分别统计各组细胞的S期细胞所占比例,结果显示实施例1-3、对比例1-6组S期细胞较对照组明显增加,差异有统计学意义;比较各组G2期细胞的比例,结果发现实施例1-3组G2期细胞比例较对照组明显增加,差异均具有统计学意义。而更为重要的是实施例1-3组将HepG2细胞阻滞于S和G2期的能力较对比例1-6更为明显,揭示本发明提供的复方三参汤有助于提高抑制肿瘤细胞的增殖生长的能力。
表4各组肺癌细胞A549不同周期细胞所占比例
表中,a表示与对照组相比,p<0.05;b表示与对比例2-6任一项比较,p<0.05。
由表4可知,与对照组比较,不同中药配方对A549肺癌细胞周期起到阻滞作用,主要表现为将细胞阻滞于GO/G1期。分别统计各组细胞的G0/G1期细胞所占比例,结果显示实施例1-3、对比例1-6组S期细胞较对照组明显增加,差异有统计学意义。而更为重要的是实施例1-3组将HepG2细胞阻滞于GO/G1期的能力较对比例1-6更为明显,差异具有统计学意义,揭示本发明提供的复方三参汤有助于提高抑制肿瘤细胞的增殖生长的能力。。
试验例2对裸鼠体内肿瘤细胞的抑制作用
本试验例以实施例1-3、对比例1-6的中药配方对A549肺癌细胞裸鼠移植瘤生长的影响。
1.1药剂准备:根据实施例1-3、对比例1-6的中药配方及工艺制得的汤剂均喷雾干燥并压制成颗粒;每种配方均取0.8g,加入到40ml生理盐水中,充分震荡到完全溶解后,离心取上清液,并经0.22um过滤器过滤后,制得20mg/ml的母液备用。
1.2实验方法
取对数生长期的A549细胞,调整至细胞浓度为5×107个/mL,在小鼠背部皮下接种A549细胞0.1ml,待皮下移植瘤体积达70mm3左右时,将其随机分为10组,每组6只。对照组:生理盐水;实施例1-3、对比例1-6组:均按1.5g/(kg·BW)进行灌胃(即换算成灌胃20mg/ml的母液);
接种48h后,将上述组别分别采用腹腔注射的方式,每日给药1次,连续3周,末次给药48h后脱臼处死小鼠,切除移植瘤,称取瘤重并计算抑瘤率,如表4所示。抑瘤率(%)=(1-实验组瘤重均值/对照组瘤重均值)×100%。
表5各组对A549细胞裸鼠瘤生长的影响
表中,a表示与对照组相比,p<0.05;b表示与对比例2-6任一项比较,p<0.05。
从表5可知,与对照组相比,相较于对照组,实施例1-3、对比例1-6组对A549细胞裸鼠移植瘤生长的抑制作用均具有显著性差异,而与对比例2-6组相比,实施例1-3组、对比例1对A549细胞裸鼠移植瘤生长的抑制作用均具有显著性差异。通过对比,可以发现:本发明复方三参汤的配伍合理,特别是灰树花、枸杞、白花蛇舌草、五味子一起协助人参、海参、地参,对肿瘤抑制效果起到了协同增效的作用,缺少人参、地参、灰树花、白花蛇舌草、五味子任一个成分,其肿瘤抑制效果显著性降低;同时实施例1-3相较于对比例1肿瘤抑制效果更为明显,说明本发明提供的制备工艺有助于增强肿瘤抑制效果。
试验例3复方三参汤对免疫调节作用的实验
实验方法:取小鼠66只,随机分为11组,分别为正常对照组,荷瘤对照组和实施例1-3、对比例1-6药剂处理组;正常对照组为常规喂养小鼠,荷瘤对照组和处理组均为接种A549肺癌细胞的小鼠,且荷瘤对照组不给药;采用常规接种A549肺癌细胞,接种后48小时,处理组分别灌服实施例1-3、对比例1-6药剂,按1.5g/(kg·BW)进行灌胃,2周后小鼠眼球采血。测定IgA、IgG、IgM含量,具体实验结果见表5。
表6各组对小鼠IgA、IgG、IgM的影响
组别 | IgA | IgG | IgM |
正常对照组 | 88±3.1 | 867±16.4 | 79±5.4 |
荷瘤对照组 | 59±4.5 | 512±17.3 | 48±3.9 |
实施例1 | 81±5.6 | 806±16.4 | 70±6.5 |
实施例2 | 82±4.3 | 812±13.9 | 71±5.1 |
实施例3 | 84±6.7 | 817±15.8 | 73±4.2 |
对比例1 | 78±5.4 | 789±16.5 | 68±3.7 |
对比例2 | 68±4.8 | 631±15.3 | 57±4.5 |
对比例3 | 72±5.7 | 662±14.6 | 61±5.8 |
对比例4 | 70±3.2 | 646±13.7 | 59±6.1 |
对比例5 | 73±3.7 | 673±15.8 | 62±6.3 |
对比例6 | 65±4.9 | 625±16.7 | 55±5.9 |
由表6可知:接种A549肺癌细胞的小鼠,免疫球蛋白IgA、IgG、IgM含量明显低于正常对照小鼠;本发明的复方三参汤可以提高小鼠已经低下的IgA、IgG、IgM含量,表明其具有免疫促进作用,可以提高肿瘤患者自身的免疫功能,从而有利于改善肿瘤患者生活质量和促进自身抗肿瘤作用。
与对照组相比,相较于对照组,实施例1-3、对比例1-6组免疫促进作用均具有显著性差异,而与对比例2-6组相比,实施例1-3组、对比例1免疫促进作用均具有显著性差异。
综上所述,本发明通过体外抗肿瘤实验、对裸鼠体内肿瘤细胞的抑制作用实验和对免疫调节作用的实验发现:以人参、海参、地参为君药,以灰树花、枸杞、白花蛇舌草、五味子为臣药,以茯苓、黄精、薏苡仁、陈皮、生姜、白术、当归为佐药,以甘草为使药,配制成的中药组合物具有显著的抗肿瘤、提高免疫力的作用。
以上所述实施例仅表达了本发明的具体实施方式,其描述较为具体和详细,但并不能因此而理解为对本发明保护范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。
Claims (8)
1.一种抗癌、增加免疫力的复方三参汤,其特征在于,按重量份计,包含以下原料:人参2~5份、海参提取物4~7份、地参8~10份、灰树花8~10份、枸杞10~12份、白花蛇舌草16~20份、五味子10~14份、茯苓16~20份、黄精8~10份、薏苡仁28~32份、陈皮5~7份、生姜8~10份、白术4~7份、当归5~8份、甘草5~8份。
2.根据权利要求2所述的一种抗癌、增加免疫力的复方三参汤,其特征在于,按重量份计,包含以下原料:人参3份、海参提取物6份、地参9份、灰树花9份、枸杞12份、白花蛇舌草18份、五味子12份、茯苓18份、黄精9份、薏苡仁30份、陈皮6份、生姜9份、白术6份、当归6份、甘草6份。
3.一种如权利要求1所述的抗癌、增加免疫力的复方三参汤的制备方法,其特征在于,包括以下步骤:
S1、取人参、地参,加醇提取,收集渗滤液;
S2、取灰树花、枸杞、白花蛇舌草、五味子、甘草,加水提取,得水相滤液;
S3、在所述醇提取液中加入所述水相滤液,混合均匀,水浴蒸煮后备用;
S4、取茯苓、黄精、薏苡仁、陈皮、生姜、白术、当归,加水煎煮后,过滤,向滤液中加入步骤S3得到的药物和海参提取物中,混合搅匀后,根据需要浓缩得到抗癌、增加免疫力的复方三参汤。
4.根据权利要求3所述的制备方法,其特征在于,步骤S1中,以醇溶液浸泡人参、地参,使其充分溶胀24h后渗滤收集渗滤液;其中,醇溶液为无水乙醇或95%的乙醇水溶液,醇溶液的质量为人参、地参的质量之和的6~10倍。
5.根据权利要求3所述的制备方法,其特征在于,步骤S1中,加入水的质量为灰树花、枸杞、白花蛇舌草、五味子、甘草的质量之和的10~12倍,加水处理时间为3~5h。
6.根据权利要求3所述的制备方法,其特征在于,步骤S4中,煎煮加入的水的质量为茯苓、黄精、薏苡仁、陈皮、生姜、白术、当归的质量之和的10~12倍,煎煮时间为3~5h。
7.一种抗癌、增加免疫力的复方制剂,其特征在于,包括如权利要求1所述的复方三参汤和可药用载体或助剂。
8.根据权利要求7所述的复方制剂,其特征在于,其剂型为颗粒剂、片剂、胶囊、丸剂、冲剂或口服液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210474046.1A CN114848786B (zh) | 2022-04-29 | 2022-04-29 | 一种抗癌、增加免疫力的复方三参汤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210474046.1A CN114848786B (zh) | 2022-04-29 | 2022-04-29 | 一种抗癌、增加免疫力的复方三参汤 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114848786A true CN114848786A (zh) | 2022-08-05 |
CN114848786B CN114848786B (zh) | 2024-01-16 |
Family
ID=82634549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210474046.1A Active CN114848786B (zh) | 2022-04-29 | 2022-04-29 | 一种抗癌、增加免疫力的复方三参汤 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114848786B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117838829A (zh) * | 2024-01-09 | 2024-04-09 | 南京中医药大学 | 一种改善炎症关联性疲劳的中药组合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1205880A (zh) * | 1996-01-23 | 1999-01-27 | 陈明 | 免疫防癌抗癌药物 |
CN1539458A (zh) * | 2003-10-30 | 2004-10-27 | 吉林省辽源亚东药业股份有限公司 | 一种抗癌参芪扶正中药制剂及制备方法 |
CN110917291A (zh) * | 2019-12-12 | 2020-03-27 | 江苏康缘药业股份有限公司 | 一种具有提高免疫力功能的组合物及其制备方法和应用 |
-
2022
- 2022-04-29 CN CN202210474046.1A patent/CN114848786B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1205880A (zh) * | 1996-01-23 | 1999-01-27 | 陈明 | 免疫防癌抗癌药物 |
CN1539458A (zh) * | 2003-10-30 | 2004-10-27 | 吉林省辽源亚东药业股份有限公司 | 一种抗癌参芪扶正中药制剂及制备方法 |
CN110917291A (zh) * | 2019-12-12 | 2020-03-27 | 江苏康缘药业股份有限公司 | 一种具有提高免疫力功能的组合物及其制备方法和应用 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117838829A (zh) * | 2024-01-09 | 2024-04-09 | 南京中医药大学 | 一种改善炎症关联性疲劳的中药组合物 |
CN117838829B (zh) * | 2024-01-09 | 2024-08-27 | 南京中医药大学 | 一种改善炎症关联性疲劳的中药组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN114848786B (zh) | 2024-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101181529B (zh) | 一种治疗肿瘤的中药组合物及其制备方法 | |
CN100361689C (zh) | 降脂颗粒组合物及其制备方法 | |
CN101904974B (zh) | 一种治疗恶性肿瘤疾病的中药组合物及其制备方法 | |
CN101711848B (zh) | 一种辅助治疗肿瘤的中药组合物 | |
CN103550506B (zh) | 一种用于放疗中配合使用的中药组合物 | |
WO2018166151A1 (zh) | 一种用于治疗肿瘤的中药组合物及其制备方法和用途 | |
CN114848786B (zh) | 一种抗癌、增加免疫力的复方三参汤 | |
CN111514266B (zh) | 一种提高紫杉醇节律化疗治疗胃癌转移疗效的药物组合物及其制备方法和应用 | |
CN116850223A (zh) | 具有调节免疫功能的黄芪扶正茶及其制备方法 | |
CN102028924B (zh) | 一种用于晚期胃癌的药物组合物 | |
CN108782905A (zh) | 桦褐孔菌保健茶及其制作方法和应用 | |
CN109893574A (zh) | 一种中药组合物、由其制备汤剂的方法以及由该方法制备的中药汤剂 | |
CN101007052A (zh) | 一种抗肿瘤药物及其制备方法 | |
CN110403967B (zh) | 一种增加人参皂苷Rg3、Rh2含量的人参加工方法及得到的加工人参和应用 | |
CN106511915A (zh) | 一种复方中药组合物在抑制皮肤黑色素瘤肺转移药物中的应用 | |
CN103169844B (zh) | 具有抗肺癌和肝癌作用的中药组合物 | |
CN106109917A (zh) | 一种治疗甲状腺瘤的外用理疗液 | |
CN111557968A (zh) | 一种具有调节免疫功能的中药复方组合物与应用 | |
CN112717097A (zh) | 一种治疗胃癌的中药组合物及其制备方法 | |
CN1042495C (zh) | 一种益气消癌升高白细胞的药物及其制备方法 | |
CN107281212B (zh) | 一种大枣复合多糖组合物及其制备方法和应用 | |
CN104857276A (zh) | 一种治疗恶性肿瘤放、化疗后气阴两虚证的中药 | |
CN105616961A (zh) | 一种中药辅助恶性肿瘤放化疗的药物及其制备方法 | |
CN102920786A (zh) | 制备能护肝脏、抗肿瘤、降血脂、调节免疫力制剂的方法 | |
CN117323358A (zh) | 一种华蟾素复方制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |